Danaher's board announced that Julie Sawyer Montgomery will assume the roles of President and Chief Executive Officer on Oct 1, 2026. The company and many investors framed the move as a planned succession that preserves operational continuity and builds on a proven track record within the firm.
Sawyer Montgomery is an internal appointment. She joined Danaher in 2017 and advanced to Executive Vice President of the Diagnostics platform, a division she has overseen through substantial expansion. Under her leadership that business roughly doubled in top-line size and delivered a material uplift in profitability.
Performance of the Diagnostics platform
The Diagnostics unit is central to the case for the promotion. When Sawyer Montgomery joined Danaher in 2017, the Diagnostics platform generated about $6.0 billion in revenue. Today that revenue sits near $11.0 billion. Over the same period operating profit in that platform increased to approximately three times its earlier baseline.
Those figures include results from businesses such as Beckman Coulter Diagnostics, which she led as President beginning in 2020. The combination of nearly 83% growth in revenue and a tripling of operating profit within the platform is presented by the company as evidence of scalability and disciplined execution rather than incremental improvement.
Mergers and acquisitions experience
Beyond organic expansion, Sawyer Montgomery has played a lead role on acquisitions. She directed the Masimo acquisition and is overseeing the pending StatLab acquisition. Management and investors have pointed to that deal experience as relevant, given Danaher’s historical reliance on bolt-on acquisitions as a component of growth.
Transition planning and near-term outlook
Danaher stated that the change in leadership does not alter its guidance for the third quarter or for the full year 2026. The company also said outgoing CEO Rainer Blair will remain available as a senior advisor through Mar 31, 2027, providing an explicit runway for the transition and an element of continuity for investors and customers.
Market framing
Supporters of the appointment point to the Diagnostics platform’s revenue expansion from approximately $6.0 billion to about $11.0 billion and the threefold increase in operating profit as a concise rationale: investors are effectively betting that Sawyer Montgomery’s operating approach can be applied more broadly across Danaher’s portfolio.
At the same time, observers caution that managing a single platform differs from overseeing the entire conglomerate, and the company will be monitored to see whether the operational approach that succeeded at Diagnostics can translate across multiple segments with differing dynamics.